Hydralazine prevents angiotensin II-induced immune cell infiltration and neuroinflammation
Co-treatment with hydralazine prevented angiotensin II-induced increases in CD45+ leukocytes in the brain (Figure 4A and 4B), including T cells (Figures 4C and 4D), myeloid cells (Figure 4E), neutrophils (Figure 4F), monocytes (Figures 4G and 4H) and B cells (Figure 4J). Numbers of macrophages were not different among all groups (Figure 4I).
Angiotensin II promoted gene expression of chemokine (C-C motif) receptor 2 (CCR2) (Figure 5A), chemokine (C-C motif) ligand 2 (CCL 2) (Figure 5B), CCL8 (Figure 5D) and TNF-α (Figure 5E) but had no effect on CCL7 (Figure 5C) and interleukin-1β (Figure 5F). Co-treatment with hydralazine prevented the angiotensin II-induced increases in gene expression of CCR2 (Figure 5A), CCL2 (Figure 5B), CCL8 (Figure 5D) and TNF- α (Figure 5E).